Navidea Biopharmaceuticals Inc EBIT margin
Mi az Navidea Biopharmaceuticals Inc EBIT margin?
A EBIT margin az Navidea Biopharmaceuticals Inc - -48,917.99%
Mi a EBIT margin meghatározása?
EBIT margin is a profitability ratio that measures earnings of the company as a percentage of revenue without taking into account the effect of taxes and interest.
ttm (trailing twelve months)
EBIT margin measures the profitability and operational efficiency of a company. It compares the amount of money that remains after the cost of goods and all operating expenses are subtracted from net revenue to sales. EBIT margin is calculated as earnings before interest and taxes divided by net revenue.
EBIT and EBIT margin evaluate how well a business manages its operations. Interest and taxes are not operating expenses and don’t impact operating efficiency. EBIT margin is usually used to compare operational efficiency and profitability of companies within the same industry. Taxes can vary by location thus excluding them from the calculation gives a better basis for comparing different companies.
EBIT and operating income are often used interchangeably, but there is a difference between them, which can cause the numbers to give different results. The key difference is that operating income does not include non-operating income, non-operating expenses, and other income.
EBIT margin a Health Care szektor a NYSEMKT-on cégekben a Navidea Biopharmaceuticals Inc -hoz képest
Mit csinál Navidea Biopharmaceuticals Inc?
navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de
ebit margin -hoz hasonló cégek Navidea Biopharmaceuticals Inc
- CytoDyn nak EBIT margin -59,324.00% van
- Chimerix Inc nak EBIT margin -58,820.14% van
- AXIM Biotechnologies nak EBIT margin -55,290.32% van
- Checkpoint Therapeutics Inc nak EBIT margin -54,444.87% van
- Actinium Pharmaceuticals Inc nak EBIT margin -52,620.99% van
- Proteo nak EBIT margin -52,352.18% van
- Navidea Biopharmaceuticals Inc nak EBIT margin -48,917.99% van
- Aimmune Therapeutics Inc nak EBIT margin -47,729.39% van
- Forward Water Technologies nak EBIT margin -46,769.19% van
- iBio Inc nak EBIT margin -46,066.00% van
- Amarillo Biosciences nak EBIT margin -45,541.62% van
- INmune Bio nak EBIT margin -44,402.35% van
- Mirasol Resources nak EBIT margin -40,845.73% van